Director Elections
ISS adopted a new policy with regards to non-employee director (“NED”) compensation as this topic has drawn the “corporate governance spotlight” in recent years. ISS will give adverse vote recommendations for board or committee members who are responsible for setting or approving NED compensation when ISS identifies a recurring pattern of excessive NED pay. The new policy will not affect vote recommendations in 2018 and would only be triggered after a pattern of excessive NED pay has been identified over two or more consecutive years.
In addition, ISS updated its policy with regards to boards that have adopted or renewed a poison pill that was not previously approved by the shareholders. Going forward, ISS will recommend against all board nominees each year as long as the company maintains a long-term poison pill (duration of more than 1 year) that has not been approved by shareholders. ISS will no longer consider a board’s undertaking to put a long-term pill to a vote of shareholders the following year as a “mitigating factor” when assessing the pill. Previously grandfathered boards of companies with 10-year pills from 2009 will no longer be exempt from negative vote recommendations from ISS. ISS will continue to evaluate adoptions of short-term pills (duration of 1 year or less) on a case-by-case basis, however, ISS will pay closer attention to the “rationale for their adoption” than on the company’s track record and corporate governance. Consistent with ISS’ current policy, renewals or extensions of existing pills will not be assessed on a case-by-case basis.
Shareholder Proposals
ISS adopted a new policy with regards to shareholder proposals related to gender pay gaps. Shareholder proposals that request reports on a company’s pay data by gender or on a company’s policies and goals for reducing existing gender pay gaps will be evaluated on a case-by-case basis. In its assessment of these specific proposals, ISS will consider the following factors when providing its recommendation:
- The company’s current policies and disclosures related to its diversity and inclusion policies and practices;
- The company’s compensation philosophy and use of fair and equitable compensation practices;
- Whether the company has been the subject of recent controversies, litigation or regulatory actions related to gender pay gap issues; and
- Whether the company’s reporting regarding gender pay gap policies or initiatives lags its peers.
Please contact the Olshan attorney with whom you regularly work or one of the attorneys listed if you would like to discuss further or have questions.
This publication is issued by Olshan Frome Wolosky LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising.
Copyright © 2017 Olshan Frome Wolosky LLP. All Rights Reserved.
PartnerSteve is foremost counsel to clients in the market's most significant domestic and cross-border shareholder activism matters, advising on some of the most high-profile activist campaigns year in and year out. Clients regularly ...
PartnerLeading activist hedge funds and investors choose Andy to guide them in their shareholder activism campaigns, proxy fights, 13D filings, hostile takeovers, corporate governance matters, and engagements with public company ...
PartnerFor over two decades, Ron has focused exclusively on representing and advising clients in shareholder activism campaigns and on related corporate governance matters.
Numerous hedge funds and other large investors retain Ron for ...